Drugs Made In America Acquisition (DMAAR) EBITDA (2025)

Drugs Made In America Acquisition (DMAAR) reported EBITDA of -$2.1 million for Q4 2025, down 692.36% quarter-over-quarter from -$263703.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) EBITDA (2025) Analysis & Trends

Drugs Made In America Acquisition has reported EBITDA for 1 years, with the latest figure at -$2.1 million in Q4 2025.

For the quarter ending Q4 2025, EBITDA changed N/A year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2025 stood at -$2.8 million (changed N/A YoY), and the FY2025 full-year result was -$2.8 million, down 906.28% from the prior year.
EBITDA for Q4 2025 stood at -$2.1 million, down from -$263703.0 in the prior quarter.
The five-year high for EBITDA was -$131919.0 in Q2 2025, with the low at -$2.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	EQV Ventures Acquisition	477.69 Mn	477.69 Mn	-	-427,850.00
2	Berto Acquisition	312.46 Mn	312.46 Mn	-	-482,100.00
3	Centurion Acquisition	311.65 Mn	311.65 Mn	-	-201,744.00
4	GP-Act III Acquisition	311.36 Mn	311.36 Mn	-	-84,204.00
5	Churchill Capital Corp IX	310.79 Mn	310.79 Mn	-	-1.15 Mn
6	WEN Acquisition	309.15 Mn	309.15 Mn	-	-225,545.00
7	Bold Eagle Acquisition	275.54 Mn	275.54 Mn	-	-198,194.00
8	Soulpower Acquisition	264.91 Mn	264.91 Mn	-	685,558.00
9	BTC Development	262.16 Mn	262.16 Mn	-	-540,761.00
10	Drugs Made In America Acquisition	-	-	-	-2.09 Mn

Download Data